Listen on the go
    • CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Céline Mascaux

    Strasbourg University, Strasbourg, France

    Prof. Céline Mascaux is a professor of thoracic oncology at Strasbourg University and head of the pulmonology department at Strasbourg University Hospitals in Strasbourg, France. read more

    Prof. Mascaux is a renowned oncologist specializing in lung cancer. She has held academic and clinical positions at several prestigious institutions, including the Jules Bordet Cancer Center in Brussels, Belgium; the University of Colorado in Denver, CO, USA; Boston University in Boston, MA, USA; and the Princess Margaret Cancer Center in Toronto, ON, Canada.

    Prof. Mascaux’s research focuses on advancing the understanding and treatment of lung cancer, particularly through innovative therapies and precision medicine. She is recognized for her expertise in both clinical practice and research, contributing significantly to the field of oncology.

    Prof. Céline Mascaux discloses: Advisory board or panel fees from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Kephren, Merck Sharp & Dohme, Pfizer, Roche, Sanofi and Takeda. Consultancy fees from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Kephren, Merck Sharp & Dohme, Pfizer, Roche, Sanofi and Takeda.
    touchRESPIRATORY touchRESPIRATORY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Lung Cancer

    Lung Cancer Content

    Lung Cancer
    Watch Time: 20 mins
    touchFOCUS
    Focused insights: Data implications of ADCs in NSCLC treatment
    CE/CME ACCREDITED Prof. Céline Mascaux

    Watch a lung cancer expert discuss the latest data for ADCs in NSCLC and their implications for clinical practice.

    Learning objectives
    Learning Objectives
    • Discuss how the evidence for the introduction of ADCs in second-line NSCLC changes the current treatment paradigm
    • Assess the latest data for ADCs in NSCLC and how they compare to standard of care approaches in terms of efficacy and safety
    Lung Cancer
    Watch Time: 99 mins
    touchCLINICAL PERSPECTIVES
    Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
    CE/CME ACCREDITED Dr Helena Yu, Dr Antonio Passaro, Dr Aaron Lisberg, Dr Sara Pilotto, Ms Jackie Fenemore, Prof. Egbert Smit Translations available:

    Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.

    Learning objectives
    Learning Objectives
    • Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing
    • Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes
    • Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes
    Lung Cancer
    Watch Time: 39 mins
    touchMDT
    Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
    CE/CME ACCREDITED Dr Lizza Hendriks, Dr Jacob Sands, Prof. Suresh Senan Translations available:

    A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).

    Learning objectives
    Learning Objectives
    • Evaluate the potential role of immune checkpoint inhibitors in the treatment of patients with limited-stage small cell lung cancer
    • Recall the latest data for ICIs in LS-SCLC
    • Examine the possible impact of ICIs on the management of patients with LS-SCLC
    Lung Cancer
    Watch Time: 55 mins
    touchMDT
    Precision targeting of MET in NSCLC: A multidisciplinary approach
    CE/CME ACCREDITED Dr Xiuning Le, Dr Christine Argento, Dr Sandra Cuellar, Ms Stephanie McDonald, Prof. Albrecht Stenzinger

    A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

    Learning objectives
    Learning Objectives
    • Recognize the importance of identifying patients with MET alterations in NSCLC and choose the most appropriate strategy to detect specific gene alterations
    • Evaluate the evidence from completed or ongoing clinical trials on the use of MET inhibitors in selected patients with advanced NSCLC and implications for future practice
    • Apply clinical trial data on MET inhibitors in NSCLC, including adverse event management, using an holistic approach to patient care
    Lung Cancer
    Watch Time: 41 mins
    touchPANEL DISCUSSION
    Expanding HER2 horizons: Implications for NSCLC and beyond
    CE/CME ACCREDITED Dr Razelle Kurzrock, Dr Lyudmila Bazhenova, Dr Ignacio Wistuba Translations available:

    Two oncologists and a pathologist discuss the implications of HER2 targeting in solid tumours, with a focus on NSCLC.

    Learning objectives
    Learning Objectives
    • Evaluate the clinical implications for tissue-agnostic HER2-targeted treatments for patients with advanced cancer
    • Discuss the latest data for HER2 targeting therapies in patients with advanced NSCLC and HER2 alterations
    • Outline best practices and guidelines for biomarker testing to establish HER2 status in patients with advanced NSCLC
    Lung Cancer
    Watch Time: 37 mins
    touchIN CONVERSATION
    Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
    CE/CME ACCREDITED Prof. Enriqueta Felip, Prof. Keith Kerr Translations available:

    An oncologist and a pathologist discuss HER2 testing and treatments for HER2-altered NSCLC.

    Learning objectives
    Learning Objectives
    • Describe the specific types of HER2 alterations and HER2 testing requirements in NSCLC
    • Discuss optimal approaches for testing HER2 alterations in NSCLC and implications for their implementation into routine clinical practice
    • Recall whether HER2 status determines treatment response and outcomes in patients with NSCLC receiving HER2-targeted therapies in NSCLC
    Lung Cancer
    Watch Time: 33 mins
    touchEXPERT OPINIONS
    Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines
    CE/CME ACCREDITED Prof. Heather A Wakelee Translations available:

    Prof. Wakelee discusses the latest evidence on immunotherapy for early-stage, resectable NSCLC.

    Learning objectives
    Learning Objectives
    • Recall the recent advances in immunotherapy for early-stage NSCLC in the neoadjuvant/adjuvant settings
    • Describe how immunotherapy fits in the treatment algorithm for early-stage NSCLC
    • Summarize the key eligibility criteria for neoadjuvant/adjuvant immunotherapy, including clinical characteristics and biomarkers
    Lung Cancer
    Watch Time: 15 mins
    touchFOCUS
    Current treatments and unmet needs in limited-stage small cell lung cancer
    CE/CME ACCREDITED Dr Anne Chiang

    A medical oncologist shares her insights on the current treatments for LS-SCLC and the remaining unmet needs

    Learning objectives
    Learning Objectives
    • Describe the current treatment landscape for limited-stage small cell lung cancer
    • Discuss the unmet treatment needs for patients with limited-stage small cell lung cancer
    Lung Cancer
    Watch Time: 34 minutes
    touchTALKS
    Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
    CE/CME ACCREDITED Dr Rebecca Heist Translations available:

    Dr Rebecca Heist discusses emerging antibody-drug conjugates for the second-line treatment of patients with advanced non-small cell lung cancer.

    Learning objectives
    Learning Objectives
    • Recognize the shared mechanisms of action of ADCs and how their different targets and payloads may inform selection in advanced/metastatic NSCLC
    • Assess the latest clinical trial data for ADCs in patients with advanced/metastatic NSCLC in the second-line setting and identify the advantages and limitations of ADCs
    • Evaluate how ADCs can be integrated into the treatment pathway for patients with advanced/metastatic NSCLC to facilitate disease management
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup